Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTR006 PET Imaging in AD and MCI
NCT06151808Completed
- Sponsor
- Sinotau Pharmaceutical Group
- Start
- Sep 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of florquinitau in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (3 arms), sponsored by Sinotau Pharmaceutical Group. Primary endpoints: Sensitivity and specificity of XTR006 PET imaging by reading at Day 1 and Sensitivity and specificity of XTR006 PET imaging by SUVR at Day 1. Started Sep 2022; status: completed.
02
Drugs
florquinitau
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT06151808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06151808.